Erez Aminov - 18 Sep 2025 Form 4 Insider Report for MIRA PHARMACEUTICALS, INC. (MIRA)

Signature
/s/ Erez Aminov
Issuer symbol
MIRA
Transactions as of
18 Sep 2025
Net transactions value
$0
Form type
4
Filing time
18 Sep 2025, 20:00:04 UTC
Previous filing
03 Sep 2025
Next filing
03 Oct 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Aminov Erez Chief Executive Officer, Director C/O MIRA PHARMACEUTICALS, INC., 1200 BRICKELL AVE. SUITE 1950 #1183, MIAMI /s/ Erez Aminov 18 Sep 2025 0001986112

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MIRA Stock Options (right to buy) Award $0 +150,000 $0.000000 150,000 18 Sep 2025 Common Stock 150,000 $1.38 Direct F1, F2, F3
transaction MIRA Stock Options (right to buy) Award $0 +150,000 $0.000000 150,000 18 Sep 2025 Common Stock 150,000 $1.38 Direct F1, F2, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on September 15, 2025.
F2 The board of directors of the Company approved to reprice the options from its previous exercise price of $5.00 to $1.38. All of the other terms of the option remain unchanged.
F3 The options were previously issued to the Reporting Person on April 28, 2023, and are now fully vested.
F4 The board of directors of the Company approved to reprice the options from its previous exercise price of $6.50 to $1.38. All of the other terms of the option remain unchanged.
F5 The options were previously issued to the Reporting Person on August 17, 2023, and are now fully vested.